HALIFAX, June 12 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that stock options will be granted to the company's directors and officers, under the plan that was approved by shareholders at its Annual General Meeting in January 2009. A total of 1,800,000 options to purchase common shares of the Company will be issued. These options are at an exercise price of $0.10 per share and are exercisable for a period of three years. The grant is subject to the approval of the TSX Venture Exchange.
"Shaped by the members of our board and executive team, MedMira is steadfast in its strategic business initiatives that are driving the company forward," said Dr. James Smith, Chairman, MedMira Inc. "Our officers and directors are an engaged group of talented and experienced individuals. Their expertise is essential at this time of growth within the Company, and granting these stock options will provide the Company the ability to retain these key personnel in a highly competitive market."
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
%SEDAR: 00013053E